Top 10 CMOs - 2019
pharmatechoutlook
 Boehringer Ingelheim: Pioneering a Brave New World in Healthcare

Top 10 CMOs - 2019

Contract manufacturers play a significant role when it comes to manufacturing medical products. By partnering with the right CM, a medical device manufacturer can save plenty of time and overhead costs. Life sciences companies need CMOs due to the potential rise in the number of products that are going through preclinical and clinical development and are relying on contract manufacturing to execute their unique requirements while cutting costs.

The contract manufacturing organizations are looking at new technologies to boost economies of scale, improve manufacturing productivity, and overall efficiency. They are currently using AI to generate novel drug candidates, understanding disease mechanisms, as well as aggregating and synthesizing information. Big data analytics also plays a crucial role in the contract manufacturing industry where organizations are widely adopting data integration, master data management, and visualization tools to determine demand forecasts, production planning, inventory optimization, and operation planning data.

While pharma companies refocus their core strengths and assets, CDMOs are playing a crucial role in providing added facilities to mitigate the risk of supply shortages by supplying multisite strategies and backup capacities. To steer CIOs in the right direction while choosing the right contract manufacturing services provider, an esteemed panel of CEOs, CIOs, VCs and analysts in coordination with Pharma Tech Outlook’s editorial board have put together a list of the leading CMOs in the industry. The vendors featured in the edition have exhibited their capabilities in providing exceptional services along with a host of innovative technologies. We present to you the “Top 10 CMOs - 2019.”

Top Contract Manufacturing Organization Companies

Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. One of the world's largest pharmaceutical companies. Family-owned since it was established in 1885, headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. The company's key areas of interest are respiratory diseases, metabolism, immunology, oncology, and diseases of the central nervous system. Boehringer Ingelheim is involved in publicly funded collaborative research projects with other industrial and academic partners. In March 2019 Boehringer announced it would acquire ICD Therapeutics

www.boehringer-ingelheim.us

A CDMO that helps pharmaceutical companies reduce costs by optimizing the manufacturing processes for both small and large molecule development. In tight collaboration with its subsidiary called China Gateway that was formed in 2009, ChemPartner works with a range of customers—from big pharma firms to small virtual biotech companies. Whether it is process development, pre-formulation development, analytical method development and validation, or CMC CTD support for regulatory filings, ChemPartner’s team of chemists, engineers, quality control, quality assurance, plant operational, and support

chempartner.com

Contract Pharmacal Corp. (CPC) has set a new paradigm in the CDMO industry as the most trusted market-leading provider of high-quality, affordable pharmaceutical and nutritional products. Since opening its doors in 1971, CPC has been defining the standards of excellence that are critical to the health and well-being of communities. With its manufacturing operations entirely based in the U.S., CPC’s core competency lies in developing, manufacturing, and packaging solid dose drugs—over the counter and prescription—that include tablets, capsules, powders, and dietary supplements to cater to their growing need in the global market

cpc.com

A collaboration solution provider that maximizes the effectiveness of a company’s marketing, sales, and service teams by means of a CRM software package. By means of a comprehensive enterprise CRM, Marketing Automation and Workflow solution that supports every aspect of customer engagement, X2CRM constructs effortless customer experiences for its clients—by enabling the most optimized process and interactions. X2CRM provides companies with speed and control in a complete, secure and highly configurable CRM

indena.com

AbbVie

AbbVie

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. In 2011, Abbott Laboratories announced its plan to separate into two publicly traded companies and that’s how AbbVie came up to operate as a research-based pharmaceutical manufacturer. The company was officially listed on the New York Stock Exchange on January 2, 2013. AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. Their mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology, and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world

ABL, Inc.

ABL, Inc.

ABL utilizes its strong core of product development expertise, GMP manufacturing and immunological testing capabilities toward advancing your candidate vaccines and therapeutics through preclinical and clinical development. ABL’s experts are producing and testing today’s leading oncolytic viruses, gene therapies, immunotherapies, viral vaccines, and recombinant protein vaccines. Based in Rockville, Maryland. ABL, Inc., operates as a subsidiary of Institut Mérieux SA. The company provides contract manufacturing solutions in the areas of current good manufacturing practice cell banking aspects, process development aspects, protein therapeutics, viral vectors, and aseptic fills. It serves government agencies, academic entities, and commercial biotechnology and pharmaceutical industries online

Brammer Bio

Brammer Bio

Brammer is an experienced viral vector CDMO supporting gene and cell therapies and is focused on process and analytical development, and clinical and commercial supply. With more than a decade of experience, its 500-strong, highly skilled team has managed over 100 client projects delivering first-in-human clinical materials to accelerate our client’s products from the laboratory to patients in need. Brammer Bio, LLC develops and manufactures cell and gene therapies for pharmaceutical and biotechnology industries. It offers pre-clinical process and analytical development, process optimization, process scale-up, process and analytical qualification, and clinical and commercial supply of drug substances and formulated drug products. The company was formerly known as Brammer Biopharmaceuticals, LLC and changed its name in Brammer Bio, LLC in April 2016. Brammer Bio, LLC was incorporated in 2013 and is based in Cambridge, Massachusetts. As of April 30, 2019, Brammer Bio, LLC operates as a subsidiary of Thermo Fisher Scientific Inc

Cambrex

Cambrex

Cambrex Corporation is a life sciences company that provides products and services for small molecule active pharmaceutical ingredients (APIs). Cambrex was founded in 1981 when the CasChem group acquired the castor oil and derivatives product lines from NL Industries. In 1987, CasChem has renamed Cambrex Corporation and became listed on NASDAQ. Cambrex entered the pharmaceutical market in 1994 with the acquisition of Nobel Pharma Chemistry business, now known as Cambrex Karlskoga AB and Cambrex Profarmaco to broaden their biocatalysis platform, Cambrex acquired IEP, now known as Cambrex IEP. In 2014, they acquired Zenara Pharma to enhance its drug product formulation capabilities, including Nicotine Replacement Therapy products. Cambrex Corporation has agreed to acquire Pharma Core Inc, a private company specializing in developing, manufacturing and scaling up small molecule APIs for clinical phase projects, for approx $25 million

LSNE Contract Manufacturing

LSNE Contract Manufacturing

Lyophilization Services of New England (LSNE) is a contract manufacturing expert that has spent the past two decades helping pharmaceutical, biotech, and medical device companies get their products into the clinic or onto the commercial market efficiently and cost-effectively. LSNE is a privately held CDMO with five cGMP facilities; four located in New England and one in Madison, WI. For more than two decades, LSNE has been dedicated to providing comprehensive aseptic fill/finish, lyophilization and development services. LSNE’s proven track record of regulatory execution and compliance, along with the technical expertise and infrastructure allows LSNE to be the end-to-end development and manufacturing partner

Tri-Pac

Tri-Pac

Tri-Pac is a turnkey contract manufacturer that produces packaging alternatives for liquids, gels, and aerosol consumer goods, over-the-counter products, and medical devices. Provide the highest quality Contract Development & Manufacturing (CDMO) and Chemical Management services to marketers of aerosol, liquid and specialty packaged products while achieving results that protect and increase the value of your brand equity and ours. It helps in Researching and Developing, to Blending, Filling (aerosol, liquid, barrier packaging and bulk) and Packaging of customer supplied materials or Full- Service Procurement and Manufacturing